Cytonics Completes First-In-Human Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development.
Completion of Clinical Study Report marks conclusion of first-in-human development stage for CYT-108 JUPITER, Fla., June 30, 2026 /PRNewswire/ -- Cytonics Corporation, a clinical-stage biopharmaceutical company developing novel Alpha-2-Macroglobulin (A2M)-based therapeutics for...
Completion of Clinical Study Report marks conclusion of first-in-human development stage for CYT-108 JUPITER, Fla., June 30, 2026 /PRNewswire/ -- Cytonics Corporation, a clinical-stage biopharmaceutical company developing novel Alpha-2-Macroglobulin (A2M)-based therapeutics for...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.